|本期目录/Table of Contents|

[1]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501-505.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(05):501-505.[doi:10.3969/j.issn.1672-271X.2018.05.012]
点击复制

CD47在乳腺癌及癌旁组织中的表达及其意义()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年05期
页码:
501-505
栏目:
临床研究
出版日期:
2018-09-18

文章信息/Info

Title:
Expression and significance of CD47 in breast cancer and pericancerous tissues
作者:
陈涛; 王璇; 程凯; 马恒辉; 王婧洁; 李汉君; 曾慧娟; 王璐璐; 王少华
作者单位：210002南京，南京大学医学院附属金陵医院（南京军区南京总医院）全军普通外科研究所（陈涛、王婧洁、李汉君、曾慧娟、王璐璐、王少华），病理科（王璇、程凯、马恒辉）
Author(s):
CHEN Tao1;  WANG Xuan2;  CHENG Kai2;  MA Heng-hui2;  WANG Jing-jie1;  LI Han-jun1;  ZENG Hui-juan1;  WANG Lu-lu1;  WANG Shao-hua1
(1.Research Institute of General Surgery, 2.Department of Pathology, Jinling Hospital, Nanjing University School of Medicine/Nanjing General Hospital of Nanjing Military Region, PLA, Nanjing 210002, Jiangsu, China)
关键词:
乳腺癌; CD47; 抗肿瘤; 预后
Keywords:
breast cancer;  CD47;  anti-tumor effect;  prognosis
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2018.05.012
文献标志码:
A
摘要:
目的 研究乳腺癌组织及癌旁组织中CD47的表达及其与临床预后及病理特征的相关性。方法 分析TCGA数据库中乳腺癌CD47表达情况及其与临床预后的相关性；选取金陵医院2011-2015年期间185例乳腺癌患者，应用免疫组化方法 评价乳腺癌组织及乳腺癌旁组织中CD47的表达情况，分析其与患者临床病理特征及预后的相关性。结果 TCGA数据库中CD47基因扩增及mRNA表达上调者比例为2.6%（22/825），CD47基因表达上调组中位总生存期低于正常组（55.6个月vs 113.7个月，P=0.0256）。乳腺癌组织CD47阳性表达率为56.21%（104/185），癌旁组织中阳性表达率为12.97%（24/185），癌与癌旁组织表达差异存在统计学意义（P<0.01）。CD47表达与年龄相关（P<0.05），与雌激素受体（ER）状态、孕激素受体（PR）状态、人类表皮生长因子受体2（Her2）状态、有无淋巴结转移、临床分期及患者预后未见相关。结论 乳腺癌组织中CD47的表达显著高于癌旁组织，且与患者年龄相关，但癌组织中CD47表达与患者临床病理特征未见相关。
Abstract:
Objective To study the expression of CD47 in breast cancer tissues and pericancerous tissues and its correlation with clinical prognosis and pathological characteristics.Methods The expression of CD47 and its correlation with clinical prognosis were analyzed in The Cancer Genome Atlas (TCGA) database. From 2011 to 2015, 185 cases of breast cancer were selected in Jinling Hospital. The expression of CD47 in breast cancer tissues and pericancerous tissues was evaluated by immunohistochemistry (IHC ) assay. And its correlation with the clinicopathological features and prognosisof the patients was analyzed.Results The proportion of CD47 gene amplification and its mRNA expression increase was 2.6% (22/825) in TCGA database. The median OS of breast cancer group was lower than that in normal group (55.6 vs 113.7 months, P=0.0256). CD47 expression was detected in 56.21% (104/185) breast cancer tissues and 12.97% (24/185) pericancerous tissues (P<0.01). The expression of CD47 was related to age（P<0.05）, but there was no significant correlation with the expression of ER, PR, and Her2, lymph node metastasis, clinical stage and prognosis.Conclusion The expression of CD47 was significantly higher in breast cancer tissues than that in pericancerous tissues, which is related to age. However，there was no significant correlation between the expression of CD47 and the clinicopathological characteristics of the breast cancer patients.

参考文献/References:

[1]Siegel RL, Miller KD, Jemal A.Cancer statistics, 2018[J].CA Cancer J Clin, 2018, 68(1): 7-30.
[2]朱成宾, 潘玉琴,何帮顺.微小 RNA 多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].东南国防医药, 2015，17(1): 22-25.
[3]顾军,于泽平.乳腺癌手术后辅助内分泌治疗研究进展[J].医学研究生学报, 2012, 25(1): 107-112.
[4]陆舜,晋悦萍.肺癌免疫治疗进入2.0时代了吗[J].医学研究生学报, 2017,30(11): 1128-1131.
[5]Cerami E, Gao J, Dogrusoz U, et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J].Cancer Discov, 2012, 2(5):401-404.
[6]Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J].Sci Signal, 2013, 6(269): pl1.
[7]Brightwell R, Grzankowski K, Lele S, et al. The CD47 “don′t eat me signal” is highly expressed in human ovarian cancer[J].Gynecol Oncol, 2016，143(2): 393-397.
[8]Sick E, Jeanne A, Schneider C, et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest[J].Br J Pharmacol, 2012, 167(7): 1415-1430.
[9]Kaur S, Elkahloun AG, Singh SP, et al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer[J].Oncotarget, 2016, 7(9): 10133.
[10]Zhang H, Lu H, Xiang L, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells[J]. Proc Natl Acad Sci USA, 2015, 112(45): E6215-E6223.
[11]Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients[J].Oncotarget, 2014, 5(18): 8147-8160.
[12]Lo J, Lau EY, Ching RH, et al. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice[J].Hepatology, 2015, 62(2): 534-545.
[13]Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma[J].Cell, 2010,142(5): 699-713.
[14]Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha(SIRPa) interaction is a therapeutic target for human solid tumors[J]. Proc Natl Acad Sci USA, 2012, 109(17): 6662-6667.
[15]Berglund L, Bjrling E, Oksvold P, et al. A genecentric Human Protein Atlas for expression profiles based on antibodies[J].Mol Cell Proteomics,2008,7(10): 2019-2027.
[16]Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis[J].Cell, 2009, 138(2): 271-285.
[17]Suzuki S, Yokobori T, Tanaka N, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma[J].Oncol Rep, 2012, 28(2): 465-472.
[18]Yang SY, Choi SA, Lee JY, et al. miR-192 suppresses leptomeningeal dissemination of medulloblastoma by modulating cell proliferation and anchoring through the regulation of DHFR, integrins, and CD47[J].Oncotarget, 2015, 6(41): 43712-43730.
[19]Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1[J].Science, 2016，352(6282):227-231.
[20]Cook KL, Soto-Pantoja DR. “UPRegulation” of CD47 by the endoplasmic reticulum stress pathway controls anti-tumor immune responses[J]. Biomark Res, 2017, 5(1): 26.
[21]Kohrt HE, Nouri N, Nowels K, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer[J].PLoS Med, 2005, 2(9): e284.
[22]Santa-Maria CA, Park SJ, Jain S, et al. Breast cancer and immunology: biomarker and therapeutic developments[J].Expert Rev Anticancer Ther, 2015, 15(10): 1215-1222.
[23]Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells[J].Cell, 2009, 138(2): 286-299.

相似文献/References:

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
[2]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[3]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(05):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[4]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[5]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(05):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[6]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(05):510.[doi:10.3969/j.issn.1672-271X.2020.05.013]
[7]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(05):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
[8]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(05):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
[9]吴勤研,蓝晓红,吴波,等.基于生物信息技术分析人参皂苷防治乳腺癌的作用机制[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
　WU Qin-yan,LAN Xiao-hong,WU Bo,et al.Analysis of the mechanism of action of ginsenosides in preventing and treating breast cancer based on bioinformatics technology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(05):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
[10]林慧,陈佳菁,郭志锋,等.miR-9-5p在乳腺癌组织中的表达与生物信息学分析[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]
　LIN Hui,CHEN Jiajing,GUO Zhifeng,et al.Expression and bioinformatic analysis of miR-9-5p in breast cancer tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(05):23.[doi:10.3969/j.issn.1672-271X.2023.01.005]

备注/Memo

备注/Memo:
基金项目：南京市科技计划项目(201605003)
更新日期/Last Update: 2018-09-20